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Abstract: In order to assess the in vivo efficacy of mycotoxin binders, specific toxicokinetic 
parameters should be measured according to European guidelines. For this purpose, an 
absorption model in pigs is described with emphasis on absorption kinetics. Pigs received a 
single oral bolus of the mycotoxin deoxynivalenol alone or in combination with active 
carbon (applied as mycotoxin binder). After administration of deoxynivalenol alone, 
significant plasma amounts of deoxynivalenol were detected and kinetic parameters were 
calculated using a one compartmental model. Activated carbon completely prevented the 
absorption of deoxynivalenol as no plasma amounts could be detected. 
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1. Introduction 
The contamination of feed with mycotoxins is a continuing feed safety issue leading to economic 
losses in animal production [1]. Consequently, a variety of methods for the decontamination of feed have 
been developed, but mycotoxin detoxifying agents seem to be the most promising and are therefore most 
commonly used [2,3]. These detoxifying agents can be divided into two different classes, namely 
mycotoxin binders and mycotoxin modifiers. These two classes have different modes of action; 
mycotoxin binders adsorb the toxin in the gut, resulting in the excretion of complex toxin-binder in the 
faeces, whereas mycotoxin modifiers transform the toxin into non-toxic metabolites [4]. The extensive 
use of these additives led, in 2009 in the European Union, to the establishment of a new group of feed 
additives called mycotoxin detoxifiers. These compounds are specified as “substances for reduction of 
the contamination of feed by mycotoxins: substances that can suppress or reduce the absorption, promote 
the excretion of mycotoxins or modify their mode of action” [5]. 
The efficacy of these products has to be evaluated. In vivo efficacy trials are usually based on  
so-called unspecific parameters, evaluating animal performance, blood biochemical or hematological 
parameters, organ weight, effects on immune function, histological changes, etc. [6]. As these criteria 
are non-specific, differences obtained between treated and untreated animals cannot be solely attributed 
to the efficacy of the detoxifier. There may be confounding effects involved such as immuno-modulating 
activity of β-glucans and antioxidant action of other feed components. A possibility to distinguish 
between specific and unspecific effects is the inclusion of a group fed non-contaminated feed 
supplemented with the detoxifier. However, the European Food Safety Authority (EFSA) proposed other 
end-points based on specific toxicokinetic parameters [7]. As mycotoxin binders are deemed to adsorb 
mycotoxins in the gut, a lowered intestinal absorption is expected. According to the EFSA, the most 
relevant parameter to evaluate the efficacy of these products is the plasma concentration of these toxins 
or their main metabolites. The EFSA proposes short-term feeding trials where the mycotoxin and 
detoxifier is mixed in the feed [7]. The plasma concentrations of the mycotoxin, and the main 
metabolite(s), should be monitored over a period of at least 5 days with a presampling period of at least 
one week (steady-state design). Furthermore, unspecific parameters may be monitored as well. Such 
feeding trials are labor and cost intensive. In contrast, a toxicokinetic model where the mycotoxin is 
administered with or without mycotoxin detoxifier as a single oral administration would be less 
expensive and labor intensive to perform. 
The aim of present study was to evaluate a bolus absorption model in relation to the EFSA guidelines, 
to study the efficacy of mycotoxin detoxifiers towards the oral absorption of deoxynivalenol (DON)  
in pigs. 
2. Results and Discussion 
After single oral bolus administration of 0.05 mg DON/kg bw, quantifiable plasma amounts of DON 
were detected (Figure 1). No statistical differences in absorption parameters between males and females 
were found (data not shown). The plasma concentration-time profile fitted a one compartmental model. 
The Tmax of 1.33 h is comparable to the value of 1.65 h reported by Goyaerts and Dänicke (2006) [8]. 
The Cmax of 29.7 ng/mL on the other hand, was higher compared to [8] (15.1 ng/mL after oral dosing of 
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0.08 mg DON/kg bw). However, feed intake can influence the oral bioavailability of DON which 
explains the slightly higher Cmax in the present study with fasted pigs in comparison to fed pigs as used 
in [8]. Other kinetic parameters of DON (Table 1) were comparable to literature reports [8,9]. The major 
metabolite of DON, de-epoxydeoxynivalenol (DOM-1), was not detected in plasma in the present study. 
This correlates to previous literature reports where DOM-1 only accounted for 1.4%–1.7% of the total 
DON concentration in the systemic circulation of pigs [10]. 
Figure 1. Plasma concentration-time profile of deoxynivalenol in piglets after single oral 
bolus administration of deoxynivalenol (DON) (0.05 mg/kg bw) alone (DON, n = 4) or in 
combination with activated carbon (DON + AC, n = 4). No plasma concentrations of DON 
were detected above the limit of detection (0.05 ng/mL) in the DON + AC group. Values are 
presented as mean + SD. 
 
To test the effectiveness of this model in pigs, DON was also administered in combination with active 
carbon (AC) as it was demonstrated that it strongly adsorbs DON in broiler chickens [11]. The absorption 
of DON was completely prevented by AC as no DON, above the limit of detection (LOD), could be 
detected in plasma. This demonstrates the suitability of the absorption kinetic model to evaluate the 
efficacy of mycotoxin binders towards the oral absorption of DON in pigs. As stated, AC was used as a 
positive control because it is a universal antidote which adsorbs various compounds, including 
mycotoxins such as DON [12,13]. However, the commercial use of AC in practice should be avoided in 
order to minimize the risk of a diminished nutrient absorption as well as the impairment of nutritional 
value of the feed [12]. 
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Table 1. Main absorption kinetic parameters of deoxynivalenol (DON) after single oral 
administration of DON to piglets (0.05 mg/kg bw, n = 4). Values are presented as  
mean ± SD. 
Kinetic parameter DON 
Cmax (ng/mL) 29.73 ± 6.847 
Tmax (h) 1.33 ± 0.802 
AUC0-inf (ng.h/mL) 168.62 ± 22.682 
ka (h
−1) 3.87 ± 2.95 
T1/2a (h) 0.66 ± 0.650 
kel (h
−1) 0.26 ± 0.048 
T1/2el (h) 2.73 ± 0.477 
Vd/F (L/kg) 1.19 ± 0.024 
Cl/F (L/h/kg) 0.30 ± 0.042 
Cmax = maximal plasma concentration; Tmax = time to maximal plasma concentration; AUC0-inf = area under the 
plasma concentration-time curve from time 0 to infinite; ka = absorption rate constant; T1/2a = absorption  
half-life; kel = elimination rate constant; T1/2el = elimination half-life; volume of distribution divided by the oral 
bioavailability = Vd/F and clearance divided by the oral bioavailability = Cl/F. 
3. Experimental Section 
3.1. Chemicals, Products and Reagents 
The standard of DON, used for the animal and analytical experiments, was obtained from Fermentek 
(Jerusalem, Israel). DOM-1 was purchased from Sigma-Aldrich (Bornem, Belgium). Internal standard 
(IS), 13C15-DON, was purchased from Biopure (Tulln, Austria). The standards were stored at ≤−15 °C. 
Water, methanol and acetonitrile (ACN) were of LC-MS grade and were obtained from Biosolve 
(Valkenswaard, The Netherlands). Glacial acetic acid was of analytical grade and obtained from VWR 
(Leuven, Belgium). Millex®-GV-PVDF filter units (0.22 µm) were obtained from Merck-Millipore 
(Diegem, Belgium). 
3.2. Animal Experiment 
Eight piglets (20.2 ± 1.4 kg bw) of mixed gender were purchased (Biocentre Agrivet, Merelbeke, 
Belgium) and housed in four different compartments (±4 m2/compartment, two animals/compartment). 
The temperature was kept between 18 and 25 °C. The relative humidity was between 40% and 80%.  
An ambient day-light scheme was applied. After a one week acclimatization period, the pigs were fasted 
for 12 h followed by administration of a single oral bolus of 0.05 mg DON/kg bw by oral gavage using 
an intragastric tube. This dose resembles a feed contamination amount of 1 mg DON/kg. For this bolus 
administration, DON was dissolved in ethanol (1 mg/mL) and further diluted with tap water up to a 
volume of 10 mL. Four of the eight pigs received the DON bolus in combination with activated carbon 
(AC) (0.1 g/kg bw, resembling an inclusion amount of 2 g/kg feed) (NORIT Carbomix®, KELA Pharma, 
Sint-Niklaas, Belgium), suspended in 10 mL of tap water. Immediately after administration of the bolus, 
the intragastric tube was rinsed with 50 mL of tap water. Blood samples were drawn before (0 min) and 
at 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10 and 12 h post administration. Blood samples were taken in 
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heparinized tubes and centrifugated (2851 × g, 10 min, 4 °C). Aliquots (250 µL) of plasma samples were 
stored at ≤−15 °C until analysis. This animal experiment was approved by the Ethical Committee of 
Ghent University (Case number EC 2011-13). 
3.3. Quantification of DON in Plasma 
Samples were analyzed as previously described by Devreese et al. (2012) [14]. Briefly, 12.5 µL of 
IS and 750 µL of ACN were added to 250 µL of plasma, followed by vortex mixing (15 s) and 
centrifugation (8517 × g, 10 min, 4 °C). Next, the supernatant was transferred to another tube and 
evaporated using a gentle nitrogen (N2) stream (45 ± 5 °C). The dry residue was reconstituted in  
200 µL of water/methanol (85/15, v/v). After vortex mixing (15 s), the sample was passed through a 
Millex® GV-PVDF filter (0.22 µm) and transferred into an autosampler vial. An aliquot (5 µL) was 
injected onto the LC-MS/MS instrument. The LC system consisted of a quaternary, low-pressure  
mixing pump with vacuum degassing, type Surveyor MSpump Plus and an autosampler with 
temperature controlled tray and column oven, type Autosampler Plus, from ThermoFisher Scientific 
(Breda, The Netherlands). Chromatographic separation was achieved on a Hypersil® Gold column  
(50 mm × 2.1 mm internal diameter, particle diameter: 1.9 µm) in combination with a guard column of 
the same type (10 mm × 2.1 mm internal diameter, particle diamter: 3 µm), both from ThermoFisher 
Scientific. A gradient elution program was performed with 0.1% glacial acetic acid in water and 
methanol as mobile phases. The LC column effluent was interfaced to a TSQ® Quantum Ultra triple 
quadrupole mass spectrometer, equipped with a heated electrospray ionization (h-ESI) probe operating 
in the negative ionization mode (all from ThermoFisher Scientific). Following selected reaction 
monitoring (SRM) transitions were monitored and used for identification and quantification, 
respectively: for DON m/z 355.1 > 265.2 and 355.1 > 295.1, for DOM-1 m/z 339.1 > 459.1 and 339.1 > 
249.0 and for 13C15-DON m/z 370.1 > 279.2 and 370.1 > 310.1. The limit of quantification (LOQ) of 
DON and DOM-1 was 1 and 2 ng/mL, respectively, whereas the limit of detection (LOD) was 0.05 and 
0.04 ng/mL, respectively. 
3.4. Absorption Parameters 
Parameter analysis was performed with WinNonlin 6.3. (Pharsight, St. Louis, MO, USA). The most 
important parameters of DON were calculated: maximal plasma concentration (Cmax), time to maximal 
plasma concentration (Tmax), area under the plasma concentration-time curve from time 0 to infinite 
(AUC0-inf), absorption rate constant (ka), absorption half-life (T1/2a), elimination rate constant (kel), 
elimination half-life (T1/2el), volume of distribution divided by the oral bioavailability (Vd/F) and 
clearance divided by the oral bioavailability (Cl/F). 
4. Conclusions 
For the first time, an in vivo model was applied to evaluate the efficacy of active carbon towards the 
oral absorption of deoxynivalenol in pigs, based on absorption kinetic characteristics. Activated carbon 
completely prevented the absorption of DON from the intestinal tract. 
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